γ-Glutamyl transferase 7 is a novel regulator of glioblastoma growth

BMC Cancer

Timothy T Bui³  Ryan T Nitta³  Suzana A Kahn²  Seyed-Mostafa Razavi³  Maya Agarwal³  Parvir Aujla³  Sharareh Gholamin²  Lawrence Recht¹  Gordon Li³ 

[1] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA

[2] Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA

[3] Department of Neurosurgery, Stanford University School of Medicine, Institute for Stem Cell Biology and Regenerative Medicine, 1201 Welch Rd P309, Stanford 94305-5487, CA, USA

关键词: Glioblastoma;    Reactive oxygen species;    γ-Glutamyl transferase 7;    γ-Glutamyl transferase;   

Others  :  1161219
DOI  :  10.1186/s12885-015-1232-y

 received in 2014-09-09, accepted in 2015-03-20,  发布年份 2015

【 摘 要 】

Background

Glioblastoma (GBM) is the most malignant primary brain tumor in adults, with a median survival time of one and a half years. Traditional treatments, including radiation, chemotherapy, and surgery, are not curative, making it imperative to find more effective treatments for this lethal disease. γ-Glutamyl transferase (GGT) is a family of enzymes that was shown to control crucial redox-sensitive functions and to regulate the balance between proliferation and apoptosis. GGT7 is a novel GGT family member that is highly expressed in brain and was previously shown to have decreased expression in gliomas. Since other members of the GGT family were found to be altered in a variety of cancers, we hypothesized that GGT7 could regulate GBM growth and formation.

Methods

To determine if GGT7 is involved in GBM tumorigenesis, we modulated GGT7 expression in two GBM cell lines (U87-MG and U138) and monitored changes in tumorigenicity in vitro and in vivo.

Results

We demonstrated for the first time that GBM patients with low GGT7 expression had a worse prognosis and that 87% (7/8) of primary GBM tissue samples showed a 2-fold decrease in GGT7 expression compared to normal brain samples. Exogenous expression of GGT7 resulted in a 2- to 3-fold reduction in proliferation and anchorage-independent growth under minimal growth conditions (1% serum). Decreasing GGT7 expression using either short interfering RNA or short hairpin RNA consistently increased proliferation 1.5- to 2-fold. In addition, intracranial injections of U87-MG cells with reduced GGT7 expression increased tumor growth in mice approximately 2-fold, and decreased mouse survival. To elucidate the mechanism by which GGT7 regulates GBM growth, we analyzed reactive oxygen species (ROS) levels in GBM cells with modulated GGT7 expression. We found that enhanced GGT7 expression reduced ROS levels by 11-33%.

Conclusion

Our study demonstrates that GGT7 is a novel player in GBM growth and that GGT7 can play a critical role in tumorigenesis by regulating anti-oxidative damage. Loss of GGT7 may increase the cellular ROS levels, inducing GBM occurrence and growth. Our findings suggest that GGT7 can be a promising biomarker and a potential therapeutic target for GBM.

【 授权许可】

   
2015 Bui et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Louis D, Ohgaki H, Wiestler O, Cavanee W. Glioblastoma. WHO Classification of Tumours of the Central Nervous System. New York, New York and Philadelphia, Pennsylvania: Springer-Verlag; 2007. p. 33–49.
• [2]Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al.: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014, 370:709-22.
• [3]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
• [4]Gilbert MR, Sulman EP, Mehta MP: Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370:2048-9.
• [5]Schafer C, Fels C, Brucke M, Holzhausen HJ, Bahn H, Wellman M, et al.: Gamma-glutamyl transferase expression in higher-grade astrocytic glioma. Acta Oncol 2001, 40:529-35.
• [6]Heisterkamp N, Groffen J, Warburton D, Sneddon TP: The human gamma-glutamyltransferase gene family. Hum Genet 2008, 123:321-32.
• [7]Dominici S, Paolicchi A, Corti A, Maellaro E, Pompella A: Prooxidant reactions promoted by soluble and cell-bound gamma-glutamyltransferase activity. Methods Enzymol 2005, 401:484-501.
• [8]He X, Di Y, Li J, Xie Y, Tang Y, Zhang F, et al.: Molecular cloning and characterization of CT120, a novel membrane-associated gene involved in amino acid transport and glutathione metabolism. Biochem Biophys Res Commun 2002, 297:528-36.
• [9]Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al.: Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 2014, 13:397-406.
• [10]Pang X, Panee J: Roles of glutathione in antioxidant defense, inflammation, and neuron differentiation in the thalamus of HIV-1 transgenic rats. J Neuroimmune Pharmacol 2014, 9:413-23.
• [11]Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al.: Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008, 26:3015-24.
• [12]Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, et al.: Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 2008, 1:52. BioMed Central Full Text
• [13]Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, et al.: Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A 2008, 105:15605-10.
• [14]Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK, Wong AJ: The role of the c-Jun N-terminal kinase 2-alpha-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene 2011, 30:234-44.
• [15]Strasak AM, Rapp K, Brant LJ, Hilbe W, Gregory M, Oberaigner W, et al.: Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer Res 2008, 68:3970-7.
• [16]Lee SB, Kim JJ, Chung JS, Lee MS, Lee KH, Kim BS, et al.: Romo1 is a negative-feedback regulator of Myc. J Cell Sci 2011, 124:1911-24.
• [17]Behrend L, Henderson G, Zwacka RM: Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003, 31:1441-4.
• [18]Wei H: Activation of oncogenes and/or inactivation of anti-oncogenes by reactive oxygen species. Med Hypotheses 1992, 39:267-70.
• [19]Waris G, Ahsan H: Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006, 5:14. BioMed Central Full Text
• [20]Day RM, Suzuki YJ: Cell proliferation, reactive oxygen and cellular glutathione. Dose Response 2005, 3:425-42.
• [21]Zhang H, Forman HJ, Choi J: Gamma-glutamyl transpeptidase in glutathione biosynthesis. Methods Enzymol 2005, 401:468-83.
• [22]Lin J, Manson JE, Selhub J, Buring JE, Zhang SM: Plasma cysteinylglycine levels and breast cancer risk in women. Cancer Res 2007, 67:11123-7.
• [23]Spear N, Aust SD: Thiol-mediated NTA-Fe(III) reduction and lipid peroxidation. Arch Biochem Biophys 1994, 312:198-202.
• [24]Franzini M, Corti A, Lorenzini E, Paolicchi A, Pompella A, De CM, et al.: Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells. Eur J Cancer 2006, 42:2623-30.